Konferenzen  >  Medizin & Gesundheitswesen  >  Onkologie  >  Virtuelle Veranstaltung

The European Association for Cancer Research (EACR), with support from The Organisation of European Cancer Institutes (OECI)

This virtual event will explore how meaningful involvement of cancer advocates throughout the research process can lead to impactful cancer research. We will highlight practical examples and offer insights into how researchers, clinicians, and patient advocates can work together to bridge gaps between science and cancer care. Participants will better understand the opportunities and challenges in shaping a collaborative research culture to advance research and improve cancer care.

Chris Iliffe (Conference Officer);     Tel.: [N/A];     Email: christopher.iliffe@eacr.org

cancer research, oncology, cancer patients, patient perspective, patient advocacy, cancer care, cancer treatment, patient quality of life, cancer symptom management, cancer therapy side effects, innovative therapy development, collaborative research

Translationale Medizin, Klinische Studien,    Medizintechnik

The European Association for Cancer Research (EACR)

This conference will explore the fundamental mechanisms controlling cancer cell plasticity at multiple biological levels including the epigenome, transcriptome, metabolome, and cellular microenvironment. Our panel of expert speakers will also discuss innovative approaches to target cell plasticity using novel pharmacological interventions that aim to prevent or reverse the adaptive mechanisms cancer cells use to circumvent conventional therapies.

Chris Iliffe (Conference Officer);     Tel.: [N/A];     Email: christopher.iliffe@eacr.org

cancer research, oncology, cancer cell biology, cancer cell plasticity, cancer epigenetics, cellular microenvironment, tumour microenvironment, tumour heterogeneity, cancer transcriptomics, metabolic reprogramming in cancer, phenotypic changes in cancer, cancer progression, cancer therapy resistance, virtual academic conference

Molekularbiologie,    Translationale Medizin, Klinische Studien

The European Association for Cancer Research (EACR)

This conference will explore a seemingly paradoxical approach to cancer therapy: the deliberate hyper-activation of cancer-relevant signalling pathways. Accumulating evidence suggests that this leads to cell death caused by a further activation of cellular stress responses. Such an approach could revolutionise treatment strategies, which often cannot abate the return of resistance in advanced cancers caused by secondary mutations reactivating previously inhibited pathways. Join us on 20 and 21 January 2026 to learn the latest science in this field from our panel of globally renowned experts. They will teach you about ways to hyperactivate oncogenic signalling and how the vulnerabilities associated with this state can be identified. In doing so, you’ll gain a fundamentally different perspective on ways to treat cancer. If you work in this field, send us an abstract before 17 November 2025 for a chance to have your work featured as a Proffered Paper or in a Flash Talk presentation! Registration closes on 15 December 2025.

Conference Officer: Chris Iliffe;     Tel.: [N/A];     Email: christopher.iliffe@eacr.org

cancer research, oncology, inhibiting oncogenic signalling, cancer therapy resistance mechanisms, secondary mutations in cancer, novel cancer therapy approaches, hyperactivation of signalling pathways, vulnerabilities within hyperactivated cancer cells, drug application, novel target identification

The European Association for Cancer Research (EACR)

This conference will focus on the basic mechanisms controlling cancer cell signalling circuits at the transcriptome, proteome and phosphoproteome levels, as well as emerging concepts in cancer cell signalling and cutting-edge, OMICS-based insights. Despite decades of research, our global understanding of how cancer cell signalling circuits are controlled, and how they determine cancer progression and therapy resistance, is still far from complete. Join us online on 10 and 11 February 2026 to hear the latest science in this area from a panel of global experts. If you work in this field, submit an abstract before 15 December 2025 for a chance to have your work featured as a Proffered Paper or in a Flash Talk presentation. Register by 19 January 2026 to secure your place as a participant.

Conference Officer: Hannah Barrs;     Email: hannah.barrs@eacr.org

cancer research, oncology, cancer cell signalling, cell signalling networks, cell signalling control mechanisms, cancer progression, cancer therapy resistance, post-translational protein regulation, transcriptional gene regulation, transcriptomics, proteomics, phosphoproteomics, kinases and phosphatases, signalling rewiring, signal integration, RNA biology in cancer

The European Association for Cancer Research (EACR)

Join us online on 24 and 25 February 2026 to explore cutting-edge developments in immunotherapy, ranging from basic research to clinical applications, with a particular focus on innovative therapeutic strategies. The programme will include invited talks from leading scientists in areas such as novel NK, T and myeloid cell therapies, mRNA therapies, and new combinatorial immune checkpoint blockade strategies. It will provide a broad overview and detailed knowledge of novel targets and new therapeutic strategies in this field. If your work centres on any of the topics mentioned above, you may be able to present it at our conference! Submit an abstract by 12 January 2026 for a chance to have your work featured as a Proffered Paper or in a Flash Talk presentation! Participant registration closes on 02 February 2026.

Conference Officer: Chris Iliffe;     Email: christopher.iliffe@eacr.org

cancer research, oncology, cancer immunotherapy, next-gen approaches to cancer therapies, cancer resistance, overcoming cancer resistance, novel NK cell therapy, novel T-cell therapy, novel myeloid cell therapy, mRNA therapy, cytokine targeting, personalised immunotherapies, basic cancer research, translational cancer research, pre-clinical cancer research, clinical applications